drugset
drugset / Trial / NCT04268784

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL343 in Healthy Volunteers

NCT04268784 ↗

Phase 1 Completed 96 enrolled Denali Therapeutics Inc.
RandomizedSequentialDouble-blindTreatment

Summary

This is a Phase 1 study carried out at a single site in 88 healthy male subjects and healthy female subjects of non childbearing potential to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of DNL343.

Timeline

Start
2020-02-20
Primary completion
2021-08-03
Completion
2021-08-03

Drugs

EvaluationDrugModalityDoseRoute
Subject EVETIFATOR Small molecule — Oral

Indications

No indication recorded.